ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

BHC vs ELVN // OPERATING MARGIN

Bausch Health Companies Inc. (NYSE) VS. Enliven Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: BHC 5 — ELVN 0
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BHC VS. ELVN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC BHC ELVN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 7.60% -26.20% +33.80 BHC /roic <GO>
EV/EBITDA & P/E Valuation 10.5x — — TIE /valuation <GO>
Free Cash Flow Yield 22.00% -2.13% +24.13 BHC /fcf-yield <GO>
Operating Margin ACTIVE 17.70% — — TIE /operating-margins <GO>
Net Profit Margin 1.50% — — TIE /net-margins <GO>
Revenue Growth (YoY) 6.70% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.45 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 9/9 2/9 +7.00 BHC /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 76.7 51.0 +25.67 BHC /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 0.97 — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 19.7x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $3.33B $3.30B $31.7M BHC /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR BHC REV ELVN REV BHC GROSS % ELVN GROSS % BHC FCF ELVN FCF
FY 2025 $10.27B $0 — — $1.00B -$70.3M
FY 2024 $9.63B $0 — — $1.26B -$73.2M
FY 2023 $8.76B $0 — — $637.9M -$61.3M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BHC // BETA 0.97
ELVN // BETA —